These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23404750)
1. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120. Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750 [TBL] [Abstract][Full Text] [Related]
2. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions. Caporuscio F; Tafi A; González E; Manetti F; Esté JA; Botta M Bioorg Med Chem Lett; 2009 Nov; 19(21):6087-91. PubMed ID: 19783140 [TBL] [Abstract][Full Text] [Related]
3. Molecular docking guided structure based design of symmetrical N,N'-disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors. Sivan SK; Vangala R; Manga V Bioorg Med Chem; 2013 Aug; 21(15):4591-9. PubMed ID: 23777826 [TBL] [Abstract][Full Text] [Related]
4. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703 [TBL] [Abstract][Full Text] [Related]
5. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01. Andrianov AM; Kashyn IA; Tuzikov AV J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811 [TBL] [Abstract][Full Text] [Related]
6. CD4 mimics targeting the mechanism of HIV entry. Yamada Y; Ochiai C; Yoshimura K; Tanaka T; Ohashi N; Narumi T; Nomura W; Harada S; Matsushita S; Tamamura H Bioorg Med Chem Lett; 2010 Jan; 20(1):354-8. PubMed ID: 19926478 [TBL] [Abstract][Full Text] [Related]
8. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism]. Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191 [TBL] [Abstract][Full Text] [Related]
9. Probing of CD4 binding pocket of HIV-1 gp120 glycoprotein using unnatural phenylalanine analogues. Yu X; Talukder P; Bhattacharya C; Fahmi NE; Lines JA; Dedkova LM; LaBaer J; Hecht SM; Chen S Bioorg Med Chem Lett; 2014 Dec; 24(24):5699-5703. PubMed ID: 25453804 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor. Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829 [TBL] [Abstract][Full Text] [Related]
11. CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Narumi T; Arai H; Yoshimura K; Harada S; Hirota Y; Ohashi N; Hashimoto C; Nomura W; Matsushita S; Tamamura H Bioorg Med Chem; 2013 May; 21(9):2518-26. PubMed ID: 23535561 [TBL] [Abstract][Full Text] [Related]
12. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120. Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895 [TBL] [Abstract][Full Text] [Related]
13. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997 [TBL] [Abstract][Full Text] [Related]
14. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Teixeira C; Serradji N; Maurel F; Barbault F Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340 [TBL] [Abstract][Full Text] [Related]
15. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Neffe AT; Meyer B Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309 [No Abstract] [Full Text] [Related]
16. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4. Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions. Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676 [TBL] [Abstract][Full Text] [Related]
18. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120. Curreli F; Belov DS; Ahmed S; Ramesh RR; Kurkin AV; Altieri A; Debnath AK ChemMedChem; 2018 Nov; 13(21):2332-2348. PubMed ID: 30257071 [TBL] [Abstract][Full Text] [Related]
20. Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120. Hsu ST; Bonvin AM Proteins; 2004 May; 55(3):582-93. PubMed ID: 15103622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]